Pliant Therapeutics, Inc. (PLRX) P/E Ratio History
Deep ValueTrading at -0.5x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2020–2020
Loading P/E history...
P/E Ratio Analysis
As of June 13, 2026, Pliant Therapeutics, Inc. (PLRX) trades at a price-to-earnings ratio of -0.5x, with a stock price of $1.13 and trailing twelve-month earnings per share of $-1.83.
The current P/E is 101% below its 5-year average of 60.2x. Over the past five years, PLRX's P/E has ranged from a low of 41.2x to a high of 79.2x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.9x, PLRX trades at a 102% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 183.0x.
Relative to the broader market, PLRX trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PLRX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PLRX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
PLRX P/E vs Peers
Immunology and Inflammation Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $156B | 18.5 | 0.14Best | +1684%Best | |
| $8B | 27.1 | 1.18 | -25% | |
| $2B | 6.9Lowest | 0.67 | +817% | |
| $6B | 52.6 | - | -4% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
PLRX Historical P/E Data (2020–2020)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2020 Q3 | Sep 30 2020 | $22.65 | $0.55 | 41.2x | -32% |
| FY2020 Q2 | - | $32.46 | $0.41 | 79.2x | +32% |
Average P/E for displayed period: 60.2x
What if you invested $1,000 in PLRX back in 2020?
Total return with dividends reinvested · 6+ years of data
Calculate ReturnsHow much would $100/month in PLRX be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs PLRX Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationPLRX vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowPLRX — Frequently Asked Questions
Quick answers to the most common questions about buying PLRX stock.
What is PLRX's P/E ratio?
Pliant Therapeutics, Inc. (PLRX) trailing twelve-month P/E ratio is -0.5x, based on TTM diluted EPS of $-1.83. The 5-year average P/E is 60.2x and the historical range spans 41.2x to 79.2x.
Is PLRX stock overvalued or undervalued?
PLRX trades at -0.5x P/E, below its 5-year average of 60.2x. At the 0th percentile of its historical range (41.2x–79.2x), the stock is priced at a discount to its own history.
Is PLRX stock expensive?
No, PLRX is not expensive on a historical basis. The current P/E of -0.5x is below the 5-year average of 60.2x and sits at the 0th percentile of its valuation range.
What is PLRX's historical P/E range?
Over the past 5 years, PLRX's P/E ratio has ranged from 41.2x to 79.2x, with a median of 79.2x and an average of 60.2x. The current P/E of -0.5x places the stock at the 0th percentile of this range. Full historical data spans 2020–2020.
How does PLRX's P/E compare to the S&P 500?
PLRX trades at -0.5x P/E versus the S&P 500 median of 25.1x. The 102% discount to the market suggests lower growth expectations or perceived higher risk.
How does PLRX's valuation compare to Healthcare peers?
Pliant Therapeutics, Inc. P/E of -0.5x compares to the Healthcare sector median of 22.9x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is PLRX's PEG ratio?
PLRX PEG ratio is N/A, based on a P/E of -0.5x and EPS growth of 30.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is PLRX's earnings yield?
PLRX earnings yield is N/A, the inverse of its -0.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.